Beijing Konruns Pharmaceutical Co Ltd Total Liabilities
Beijing Konruns Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, Beijing Konruns Pharmaceutical Co Ltd (603590) has total liabilities worth CN¥569.41 Million CNY (≈ $83.32 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 603590 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Beijing Konruns Pharmaceutical Co Ltd (2013–2025)
Total liabilities of Beijing Konruns Pharmaceutical Co Ltd from 2013 to 2025. This chart illustrates how Beijing Konruns Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data.
Beijing Konruns Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Beijing Konruns Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Merida Industry Co Ltd
TW:9914
|
Taiwan | NT$15.38 Billion |
|
CREOTECH INS.S.A. ZY -10
F:5OB
|
Germany | €166.38 Million |
|
TPI POLENE POWER
BK:TPIPP-R
|
Thailand | ฿31.03 Billion |
|
UEM Sunrise Bhd
KLSE:5148
|
Malaysia | RM5.64 Billion |
|
Sundiro Holding Co Ltd
SHE:000571
|
China | CN¥1.60 Billion |
|
Foosung
KO:093370
|
Korea | ₩438.14 Billion |
|
Spearhead Integrated Marketing
SHE:300071
|
China | CN¥608.62 Million |
|
Barco NV
BR:BAR
|
Belgium | €494.52 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Beijing Konruns Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Beijing Konruns Pharmaceutical Co Ltd assets under control.
Liquidity & Leverage Metrics
Beijing Konruns Pharmaceutical Co Ltd Total Liabilities Ratios Explained
Beijing Konruns Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Beijing Konruns Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Beijing Konruns Pharmaceutical Co Ltd (2013–2025)
The table below shows the annual total liabilities of Beijing Konruns Pharmaceutical Co Ltd from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥598.51 Million ≈ $87.58 Million |
+21.27% |
| 2024-12-31 | CN¥493.52 Million ≈ $72.22 Million |
+17.94% |
| 2023-12-31 | CN¥418.44 Million ≈ $61.23 Million |
+78.31% |
| 2022-12-31 | CN¥234.68 Million ≈ $34.34 Million |
-2.52% |
| 2021-12-31 | CN¥240.74 Million ≈ $35.23 Million |
-65.69% |
| 2020-12-31 | CN¥701.72 Million ≈ $102.68 Million |
+57.39% |
| 2019-12-31 | CN¥445.84 Million ≈ $65.24 Million |
+1.45% |
| 2018-12-31 | CN¥439.48 Million ≈ $64.31 Million |
+37.80% |
| 2017-12-31 | CN¥318.93 Million ≈ $46.67 Million |
+116.41% |
| 2016-12-31 | CN¥147.37 Million ≈ $21.56 Million |
-9.33% |
| 2015-12-31 | CN¥162.53 Million ≈ $23.78 Million |
-8.18% |
| 2014-12-31 | CN¥177.02 Million ≈ $25.90 Million |
-12.23% |
| 2013-12-31 | CN¥201.68 Million ≈ $29.51 Million |
-- |
About Beijing Konruns Pharmaceutical Co Ltd
Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon acutus hemocoagulase under Suling trade name, a single-component hemocoagulase clinical hemostatic drug for surgical operations. It is also involved in the development of drug candidates, including ZY5301 that is in p… Read more